Despite an impending patent cliff in 2026 that will invite generic competition from companies like Sun Pharma and Dr. Reddy's, Emcure’s leadership believes the ‘innovator edge’ and a robust metabolic portfolio will secure long-term market dominance.
Stocks to watch. Shares of firms like RIL, Paytm, Tata Power, HCL Tech, KPIGreen, SJVN, Emcure Pharma, and others will be in focus on Tuesday's�trade ....
As part of the agreement, Emcure Pharma will be the exclusive distributor responsible for the commercialisation and marketing of Poviztra in India... .